Buy Teveten Plus pills 28 pcs
  • Buy Teveten Plus pills 28 pcs

Teveten plus [Eprosartan]

1518 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Tevet Plus has a hypotensive, vasodilating, diuretic effect.


Arterial hypertension.


1 tab. contains eprosartan mesilate 735.8 mg (corresponds to 600 mg of eprosartan), hydrochlorothiazide 12.5 mg;
Excipients: MCC - 43.3 mg; lactose monohydrate - 43.3 mg; gelatinized corn starch - 43.3 mg; crospovidone - 38.5 mg; magnesium stearate - 7.2 mg; purified water - 50.9 mg;
shell: Opadry (OY3736) - 31 mg (hypromellose, macrogol 400, dyes: titanium dioxide E171, iron oxide black E172, iron oxide yellow E172).

No customer reviews for the moment.

Write your review

Write your review

Teveten plus [Eprosartan]

Dosage and Administration

Tevet Plus take orally, 1 tab. per day, in the morning, regardless of the meal.
The selection of the dose of Teveten Plus in elderly patients, patients with mild and moderate liver dysfunction, as well as patients with impaired renal function (Cl creatinine more than 30 ml / min) is not required.

Adverse reactions

The overall incidence of side effects reported in patients taking eprosartan is comparable to that taken with placebo. These actions, as a rule, were mild and short-lived, so only 4.1% of patients who took eprosartan during placebo-controlled clinical trials took cessation of treatment (6.5% in the placebo group).
From the side of the central nervous system: seldom - headache, dizziness, asthenia.
Since the cardiovascular system: very rarely - decreased blood pressure, incl. postural hypotension.
Skin and subcutaneous adipose tissue: rarely - skin reactions (rash, itching and urticaria); very rarely - swelling of the face, angioedema.
Other: rarely cough.


Hypersensitivity to Tevetin Plus components;
breastfeeding period;
age up to 18 years (efficacy and safety have not been established).
severe heart failure III – IV FC (by NYHA);
bilateral renal artery stenosis, renal artery stenosis of a single kidney;
decrease in BCC as a result of vomiting, diarrhea, receiving high doses of diuretics.
The company does not have data on Teveten's safety in patients with terminal renal insufficiency (Cl creatinine less than 5 ml / min, uremia II), as well as in patients on hemodialysis.

Drug interactions

The antihypertensive effect may increase with simultaneous use with other antihypertensive agents.

When used in conjunction with oral hypoglycemic agents, it is necessary to adjust their dose, because hydrochlorothiazide may decrease glucose tolerance.

With simultaneous use with lithium preparations, a reversible increase in plasma lithium concentration and an increase in the risk of its toxic effects may occur (careful monitoring of lithium concentration in patients receiving this combination is necessary).

NSAIDs can reduce the diuretic and hypotensive effect of Teveten Plus.

By lowering potassium, hydrochlorothiazide may enhance the action of cardiac glycosides and some antiarrhythmic drugs.

Hydrochlorothiazide increases the risk of hypokalemia when it is prescribed together with drugs that cause the body to lose potassium, for example, diuretics that have a potassium uretic effect, laxatives, GCS and ACTH.

Hydrochlorothiazide may enhance the action of non-depolarizing muscle relaxants (for example, tubocurarine). The absorption of hydrochlorothiazide is reduced when anion exchange resins are taken together (for example, colestiramine or colestipol).

Special instructions

Based on the pharmacodynamic properties, Teveten Plus should not affect the ability to drive and use machines and mechanisms. During the treatment of hypertension, care must be taken when driving vehicles and engaging in potentially hazardous activities that require increased concentration and psychomotor speed, due to the fact that dizziness and weakness may occur.


Data on Teveten's overdose plus is currently not available. Among the symptoms, it is possible to suggest the following: an excessive decrease in blood pressure, dehydration and electrolyte imbalance (hypokalemia, hypochloremia, hyponatremia), manifested in the form of nausea and drowsiness.
Treatment depending on the time elapsed after a meal, the measures taken should include the stimulation of vomiting, gastric lavage and / or ingestion of Activated charcoal.
With a sharp decrease in blood pressure it is recommended to lay the patient on his back, lift his legs, if necessary, introduce plasma-substituting fluids. Symptomatic and supportive therapy is recommended for dehydration and impaired water-salt balance. Hemodialysis is not effective.

  • Brand name: Teveten Plus
  • Active ingredient: Eprosartan
  • Dosage form: pills, coated.
  • Manufacturer: Abbott
  • Country of Origin: USA

Studies and clinical trials of Eprosartan (Click to expand)

  1. Differentiation of Two Geometric Isomers of the Pharmaceutical Eprosartan Using Atmospheric Pressure Chemical Ionization
  2. ChemInform Abstract: A New Regioselective Synthesis of 1,2,5-Trisubstituted 1H-Imidazoles and Its Application to the Development of Eprosartan.
  3. ChemInform Abstract: Selenosartans: Novel Selenophene Analogues of Milfasartan and Eprosartan.
  4. Synthesis and biological evaluation of [carboxyl-11C]eprosartan
  5. Selenosartans: Novel selenophene analogues of milfasartan and eprosartan
  6. Validation of a solid phase extraction-high performance liquid chromatographic method for the determination of eprosartan in human plasma
  7. Uremic toxins inhibit hepatic uptake of eprosartan
  8. Determination of eprosartan in human plasma and urine by LC/MS/MS
  9. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*
  10. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men*
  11. Structure elucidation and conformational properties of eprosartan a non peptide Angiotensin II AT1 antagonist
  12. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers
  13. Effect of age and gender on the pharmacokinetics of eprosartan
  14. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension1
  15. A novel approach to treatment of hypertension in diabetic patients – a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 – rationale and design [ISRCTN55725285]
  16. Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors
  17. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials
  18. Effects of Eprosartan on Diastolic Function and Neurohormones in Patients with Hypertension and Diastolic Dysfunction
  19. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial)
  20. Characterization of a novel impurity in bulk drug eprosartan by ESI/MSn and NMR
  21. Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans
  22. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients
  23. Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe—The HEALTH Model
  24. Dehydration behavior of eprosartan mesylate dihydrate

8 other products in the same category: